HC Wainwright reissued their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Rating) in a research note issued to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a $53.00 price objective on the biotechnology company’s stock. A number of other equities research analysts have also recently commented on ATNM. StockNews.com cut […]
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Rating) had its target price hoisted by Cantor Fitzgerald from $26.00 to $27.00 in a research report report published on Tuesday, The Fly reports. Several other equities research analysts have also recently commented on the company. HC Wainwright reissued a buy rating and issued a $53.00 price target on shares […]
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Rating) released its quarterly earnings data on Monday. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01), MarketWatch Earnings reports. Actinium Pharmaceuticals had a negative return on equity of 41.64% and a negative net margin of 2,885.09%. Actinium Pharmaceuticals […]